Related Experiment Video

Updated: Apr 23, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

7.5K

Drugging the HDAC6-HSP90 interplay in malignant cells

Oliver H Krämer1, Siavosh Mahboobi2, Andreas Sellmer2

  • 1Department of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany.

Trends in Pharmacological Sciences
|September 20, 2014
PubMed

Insights

Histone deacetylase 6 (HDAC6) plays a key role in protein homeostasis and preventing aggregation. Its interaction with heat shock protein 90 (HSP90) is crucial, with implications for cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Acetylation and deacetylation cycles are vital regulatory processes.
  • Histone deacetylases (HDACs) remove acetyl groups from lysine residues.
  • HDAC6 possesses unique cytoprotective functions, maintaining protein homeostasis and preventing aggregation.

Purpose of the Study:

  • To review the complex interplay between HDAC6 and heat shock protein 90 (HSP90).
  • To explore how HSP90-dependent regulators influence HDAC6 functions.
  • To discuss the therapeutic potential of HDAC6 inhibitors, particularly in leukemia.

Main Methods:

  • Literature review focusing on HDAC6 and HSP90 interactions.
  • Analysis of posttranslational modifications (PTMs) affecting HDAC6.
  • Examination of small molecules targeting HDAC6.

Main Results:

  • The HDAC6-HSP90 interplay is complex and critical for cellular functions.
  • HSP90-dependent regulators significantly dictate HDAC6 activity.
  • HDACi-induced HSP90 acetylation may impact oncogenic proteins in leukemia.

Conclusions:

  • Understanding the HDAC6-HSP90 axis is crucial for developing targeted therapies.
  • Specific HDAC6 inhibitors show therapeutic promise, especially in hematological malignancies.
  • Structure-function relationships are key to designing specific and effective HDAC6-targeting drugs.
Keywords:
AcetylationHDAC6HDAC6 inhibitorHSP90cancerleukemia

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.3K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K